Ould-Kaci M - Search Results

1

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. Cortés J, et al. Among authors: ould kaci m. Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17. Lancet Oncol. 2015. PMID: 26596672 Clinical Trial.

2

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.

Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC. Bahleda R, et al. Among authors: ould kaci m. Br J Cancer. 2015 Nov 17;113(10):1413-20. doi: 10.1038/bjc.2015.374. Epub 2015 Oct 29. Br J Cancer. 2015. PMID: 26512876 Free PMC article. Clinical Trial.

3

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.

Marshall J, Shapiro GI, Uttenreuther-Fischer M, Ould-Kaci M, Stopfer P, Gordon MS. Marshall J, et al. Among authors: ould kaci m. Future Oncol. 2013 Feb;9(2):271-81. doi: 10.2217/fon.12.195. Future Oncol. 2013. PMID: 23414476 Clinical Trial.

4

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Wasserman E, et al. J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751. J Clin Oncol. 1999. PMID: 10561212 Clinical Trial.

5

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM. Gordon MS, et al. Among authors: ould kaci m. Future Oncol. 2015;11(10):1479-91. doi: 10.2217/fon.15.50. Future Oncol. 2015. PMID: 25963426 Clinical Trial.

6

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.

Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G. Droz JP, et al. Ann Oncol. 2003 Aug;14(8):1291-8. doi: 10.1093/annonc/mdg342. Ann Oncol. 2003. PMID: 12881395 Free article. Clinical Trial.

7

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. Gazzah A, et al. Among authors: ould kaci m. Eur J Cancer. 2018 Nov;104:1-8. doi: 10.1016/j.ejca.2018.07.011. Epub 2018 Oct 1. Eur J Cancer. 2018. PMID: 30278378 Clinical Trial.

8

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P. Ducreux M, et al. Ann Oncol. 2004 Mar;15(3):467-73. doi: 10.1093/annonc/mdh098. Ann Oncol. 2004. PMID: 14998850 Free article. Clinical Trial.

9

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL. Marshall J, et al. Among authors: ould kaci m. Invest New Drugs. 2013 Apr;31(2):399-408. doi: 10.1007/s10637-012-9890-y. Epub 2012 Nov 17. Invest New Drugs. 2013. PMID: 23161335 Free PMC article. Clinical Trial.

10

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.

Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB. Gordon MS, et al. Among authors: ould kaci m. Invest New Drugs. 2013 Apr;31(2):409-16. doi: 10.1007/s10637-012-9904-9. Epub 2012 Dec 15. Invest New Drugs. 2013. PMID: 23242861 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters